# A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

> **NCT06450366** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 301 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Enlicitide
- **DRUG:** Ezetimibe
- **DRUG:** Bempedoic Acid
- **OTHER:** Placebo for Enlicitide
- **OTHER:** Placebo for Ezetimibe
- **OTHER:** Placebo for Bempedoic Acid

## Key facts

- **NCT ID:** NCT06450366
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-08
- **Primary completion:** 2025-02-14
- **Final completion:** 2025-03-28
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06450366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06450366, "A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06450366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*